Pieris Corp (PVLA) Amount of Cash per Share

Pieris Pharmaceuticals (PVLA) fully outsources substance development and clinical trials to third-party organizations. The cash per share metric visualizes current liquidity, with 16.15 representing the latest level. Global sales flexibility is ensured through external manufacturing, while business resilience is based on the proprietary Anticalin protein system, which attracts strategic B2B partners.
Analytical breakdowns for Pieris Pharmaceuticals

This indicator calculates the proportion of liquid assets per common share, which determines the actual cash support for the security's market value. For Pieris Pharmaceuticals (PVLA), during its period of restructuring and asset portfolio review, the cash per share analysis becomes a key criterion for financial viability and the margin of safety until new partnership agreements are concluded.